Literature DB >> 20472343

Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.

Yukinori Matsuo1, Keiko Shibuya, Yasushi Nagata, Kenji Takayama, Yoshiki Norihisa, Takashi Mizowaki, Masaru Narabayashi, Katsuyuki Sakanaka, Masahiro Hiraoka.   

Abstract

PURPOSE: To investigate the factors that influence clinical outcomes after stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: A total of 101 consecutive patients who underwent SBRT with 48 Gy in 4 fractions for histologically confirmed Stage I NSCLC were enrolled in this study. Factors including age, maximal tumor diameter, sex, performance status, operability, histology, and overall treatment time were evaluated with regard to local progression (LP), disease progression (DP), and overall survival (OS) using the Cox proportional hazards model. Prognostic models were built with recursive partitioning analysis.
RESULTS: Three-year OS was 58.6% with a median follow-up of 31.4 months. Cumulative incidence rates of LP and DP were 13.2% and 40.8% at 3 years, respectively. Multivariate analysis demonstrated that tumor diameter was a significant factor in all endpoints of LP, DP, and OS. Other significant factors were age in DP and sex in OS. Recursive partitioning analysis indicated a condition for good prognosis (Class I) as follows: female or T1a (tumor diameter ≤20 mm). When the remaining male patients with T1b-2a (>20 mm) were defined as Class II, 3-year LP, DP, and OS were 6.8%, 23.6%, and 69.9% in recursive partitioning analysis Class I, respectively, whereas these values were 19.9%, 58.3%, and 47.1% in Class II. The differences between the classes were statistically significant.
CONCLUSIONS: Tumor diameter and sex were the most significant factors in SBRT for NSCLC. T1a or female patients had good prognosis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20472343     DOI: 10.1016/j.ijrobp.2009.12.022

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  44 in total

Review 1.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

2.  Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer.

Authors:  Sana D Karam; Zachary D Horne; Robert L Hong; Nimrah Baig; Gregory J Gagnon; Don McRae; David Duhamel; Nadim M Nasr
Journal:  Lung Cancer (Auckl)       Date:  2013-08-06

Review 3.  Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.

Authors:  Feng Liu; An Tai; Percy Lee; Tithi Biswas; George X Ding; Isaam El Naqa; Jimm Grimm; Andrew Jackson; Feng-Ming Spring Kong; Tamara LaCouture; Billy Loo; Moyed Miften; Timothy Solberg; X Allen Li
Journal:  Radiother Oncol       Date:  2016-11-18       Impact factor: 6.280

4.  Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.

Authors:  M Dosani; R Yang; M McLay; D Wilson; M Liu; C J Yong-Hing; J Hamm; C R Lund; R Olson; D Schellenberg
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

5.  Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer.

Authors:  Zhen Wang; Ao-Mei Li; Jie Gao; Jing Li; Bing Li; Percy Lee; Charles B Simone; Yong Song; Xi-Xu Zhu
Journal:  Transl Lung Cancer Res       Date:  2017-02

6.  A Histologic Basis for the Efficacy of SBRT to the lung.

Authors:  Neil M Woody; Kevin L Stephans; Martin Andrews; Tingliang Zhuang; Priyanka Gopal; Ping Xia; Carol F Farver; Daniel P Raymond; Craig D Peacock; Joseph Cicenia; Chandana A Reddy; Gregory M M Videtic; Mohamed E Abazeed
Journal:  J Thorac Oncol       Date:  2016-12-22       Impact factor: 15.609

7.  Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Motohiro Yamashita; Naoyuki Nogami; Yoshifumi Sugawara; Toshiyuki Kozuki; Shigeki Sawada; Hiroshi Suehisa; Syuichi Shinohara; Naomi Nakajima; Tetsu Shinkai
Journal:  Jpn J Radiol       Date:  2012-03-27       Impact factor: 2.374

8.  Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial.

Authors:  Damian E Dupuy; Hiran C Fernando; Shauna Hillman; Thomas Ng; Angelina D Tan; Amita Sharma; William S Rilling; Kelvin Hong; Joe B Putnam
Journal:  Cancer       Date:  2015-06-19       Impact factor: 6.860

9.  Safety and effectiveness of stereotactic body radiotherapy for a clinically diagnosed primary stage I lung cancer without pathological confirmation.

Authors:  Katsuyuki Sakanaka; Yukinori Matsuo; Yasushi Nagata; Sayo Maki; Keiko Shibuya; Yoshiki Norihisa; Masaru Narabayashi; Nami Ueki; Takashi Mizowaki; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

10.  Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.

Authors:  Jingjing Kang; Matthew S Ning; Han Feng; Hongqi Li; Houda Bahig; Eric D Brooks; James W Welsh; Rui Ye; Hongyu Miao; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-03       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.